Literature DB >> 33490612

Impact of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging on the prognosis of hepatocellular carcinoma after surgery.

Shingo Shimada1, Toshiya Kamiyama1, Tatsuhiko Kakisaka1, Tatsuya Orimo1, Akihisa Nagatsu1, Yoh Asahi1, Yuzuru Sakamoto1, Daisuke Abo2, Hirofumi Kamachi1, Akinobu Taketomi1.   

Abstract

BACKGROUND AND AIM: Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (EOB-MRI) has been recognized as a useful imaging technique to distinguish the biological behavior of hepatocellular carcinoma (HCC).
METHODS: We analyzed 217 hepatectomy recipients with HCCs measuring 10 cm or less. We divided the patients into a decreased intensity (DI) group (n = 189, 87%) and an increased or neutral intensity (INI) group (n = 28, 13%) according to the ratio of tumor intensity to liver intensity during the hepatobiliary phase (HBP). According to the ratio of the maximum tumor diameter (including peritumoral hypointensity) between HBP images and precontrast T1-weighted images (RHBPP), we divided the patients as follows: The group whose RHBPP was ≥1.036 was the high RHBPP group (n = 60, 28%), and the group whose RHBPP was <1.036 was the low RHBPP group (n = 157, 72%). We investigated the prognoses and clinicopathological characteristics of these patients.
RESULTS: DI versus INI was not a prognostic factor for either survival or recurrence; however, a high RHBPP was an independent predictor of unfavorable survival and recurrence in patients. In addition, the INI group showed significantly lower α-fetoprotein (AFP) levels and higher rates of well-differentiated HCC and ICGR15 ≥15% than the DI group. The high RHBPP group showed significantly higher rates of vascular invasion and poorly differentiated HCC than the low RHBPP group.
CONCLUSIONS: A high RHBPP by EOB-MRI is a preoperative predictor of vascular invasion and an unfavorable prognostic factor for survival and recurrence. These patients might be considered for highly curative operations such as anatomical liver resection.
© 2020 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Primovist; hepatocellular carcinoma; magnetic resonance imaging; portal venous invasion

Year:  2020        PMID: 33490612      PMCID: PMC7812518          DOI: 10.1002/jgh3.12444

Source DB:  PubMed          Journal:  JGH Open        ISSN: 2397-9070


  27 in total

1.  Prediction of microvascular invasion of hepatocellular carcinoma: usefulness of peritumoral hypointensity seen on gadoxetate disodium-enhanced hepatobiliary phase images.

Authors:  Kyung Ah Kim; Myeong-Jin Kim; Hyae Min Jeon; Kyung Sik Kim; Jin-Sub Choi; Sang Hoon Ahn; Soon Joo Cha; Young Eun Chung
Journal:  J Magn Reson Imaging       Date:  2011-11-08       Impact factor: 4.813

2.  Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI.

Authors:  Shi-Ting Feng; Yingmei Jia; Bing Liao; Bingsheng Huang; Qian Zhou; Xin Li; Kaikai Wei; Lili Chen; Bin Li; Wei Wang; Shuling Chen; Xiaofang He; Haibo Wang; Sui Peng; Ze-Bin Chen; Mimi Tang; Zhihang Chen; Yang Hou; Zhenwei Peng; Ming Kuang
Journal:  Eur Radiol       Date:  2019-01-28       Impact factor: 5.315

3.  Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations.

Authors:  Alexander Huppertz; Sibylle Haraida; Armin Kraus; Christoph J Zech; Juergen Scheidler; Josy Breuer; Thomas K Helmberger; Maximilian F Reiser
Journal:  Radiology       Date:  2004-12-10       Impact factor: 11.105

Review 4.  Liver Function Assessment by Magnetic Resonance Imaging.

Authors:  Emre Ünal; Deniz Akata; Musturay Karcaaltincaba
Journal:  Semin Ultrasound CT MR       Date:  2016-08-17       Impact factor: 1.875

5.  Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production.

Authors:  Yoshiki Asayama; Tsuyoshi Tajima; Akihiro Nishie; Kousei Ishigami; Daisuke Kakihara; Tomohiro Nakayama; Daisuke Okamoto; Nobuhiro Fujita; Shinichi Aishima; Ken Shirabe; Hiroshi Honda
Journal:  Eur J Radiol       Date:  2010-11-24       Impact factor: 3.528

6.  Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma.

Authors:  Masato Narita; Etsuro Hatano; Shigeki Arizono; Aya Miyagawa-Hayashino; Hiroyoshi Isoda; Koji Kitamura; Kojiro Taura; Kentaro Yasuchika; Takashi Nitta; Iwao Ikai; Shinji Uemoto
Journal:  J Gastroenterol       Date:  2009-04-29       Impact factor: 7.527

7.  Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma.

Authors:  Taro Yamashita; Azusa Kitao; Osamu Matsui; Takehiro Hayashi; Kouki Nio; Mitsumasa Kondo; Naoki Ohno; Tosiaki Miyati; Hikari Okada; Tatsuya Yamashita; Eishiro Mizukoshi; Masao Honda; Yasuni Nakanuma; Hiroyuki Takamura; Tetsuo Ohta; Yasunari Nakamoto; Masakazu Yamamoto; Tadatoshi Takayama; Shigeki Arii; XinWei Wang; Shuichi Kaneko
Journal:  Hepatology       Date:  2014-09-29       Impact factor: 17.425

8.  Diagnostic Value of Gd-EOB-DTPA-Enhanced MRI for the Expression of Ki67 and Microvascular Density in Hepatocellular Carcinoma.

Authors:  Yidi Chen; Xiali Qin; Liling Long; Ling Zhang; Zhongkui Huang; Zijian Jiang; Chenhui Li
Journal:  J Magn Reson Imaging       Date:  2019-11-01       Impact factor: 4.813

9.  Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma.

Authors:  Yi-Chen Chou; I-Ha Lao; Pei-Ling Hsieh; Ying-Ying Su; Chee-Wai Mak; Ding-Ping Sun; Ming-Jen Sheu; Hsing-Tao Kuo; Tzu-Ju Chen; Chung-Han Ho; Yu-Ting Kuo
Journal:  World J Gastroenterol       Date:  2019-06-07       Impact factor: 5.742

10.  National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003.

Authors:  Faruque Ahmed; Joseph F Perz; Sandy Kwong; Patricia M Jamison; Carol Friedman; Beth P Bell
Journal:  Prev Chronic Dis       Date:  2008-06-15       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.